More changes in cancer test services as Genzyme steps up
This article was originally published in Clinica
Executive Summary
Genzyme has emerged as the lead bidder for Impath's cancer diagnostic services business, which filed for Chapter 11 bankruptcy protection last September. Genzyme, which launched a bid for cancer drug business Ilex Oncology last week, has put $215m in cash on the table for Impath Physician Services.
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.